Published in Blood on March 01, 2002
Early chimerism threshold predicts sustained engraftment and NK-cell tolerance in prenatal allogeneic chimeras. Blood (2008) 1.73
Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood (2008) 1.62
Maternal T cells limit engraftment after in utero hematopoietic cell transplantation in mice. J Clin Invest (2011) 1.25
Maternal alloantibodies induce a postnatal immune response that limits engraftment following in utero hematopoietic cell transplantation in mice. J Clin Invest (2009) 1.16
Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues. J R Soc Interface (2010) 1.06
Systemic delivery of AAV8 in utero results in gene expression in diaphragm and limb muscle: treatment implications for muscle disorders. Gene Ther (2009) 0.84
Detection and characterization of hepatic engraftment of embryonic stem derived cells by fluorescent stereomicroscopy. J Surg Res (2007) 0.80
Influence of intrauterine injection of rat fetal hepatocytes on rejection of rat liver transplantation. World J Gastroenterol (2003) 0.80
Fetal liver cells transplanted in utero rescue the osteopetrotic phenotype in the oc/oc mouse. Am J Pathol (2009) 0.80
Induced pluripotent stem (iPS) cells from human fetal stem cells (hFSCs). Organogenesis (2013) 0.78
Transplantation tolerance induced in humans at the fetal or the neonatal stage. J Transplant (2011) 0.78
NK cell tolerance as the final endorsement of prenatal tolerance after in utero hematopoietic cellular transplantation. Front Pharmacol (2015) 0.77
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 7.28
Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood (2004) 7.09
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease. Blood (2007) 6.45
Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med (2004) 6.26
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med (2010) 6.24
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood (2010) 5.79
The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood (2002) 5.72
Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci (2010) 5.54
IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol (2007) 5.31
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Rapamycin slows aging in mice. Aging Cell (2012) 3.76
Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol (2007) 3.65
Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood (2009) 3.62
Rapid and complete donor chimerism in adult recipients of unrelated donor umbilical cord blood transplantation after reduced-intensity conditioning. Blood (2003) 3.42
Sarcoma derived from cultured mesenchymal stem cells. Stem Cells (2006) 3.40
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Protein kinase C-theta mediates negative feedback on regulatory T cell function. Science (2010) 3.31
Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant (2002) 3.29
Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity (2009) 3.21
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell (2009) 3.16
Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol (2004) 3.10
Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol (2009) 3.06
Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity (2012) 2.99
L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood (2004) 2.90
Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med (2010) 2.82
The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol (2011) 2.69
Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell (2008) 2.65
Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood (2004) 2.63
In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med (2003) 2.59
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol (2008) 2.55
An Aging Interventions Testing Program: study design and interim report. Aging Cell (2007) 2.54
Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood (2008) 2.53
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood (2009) 2.50
Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded. Tissue Eng Part A (2010) 2.44
Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell (2014) 2.35
The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol (2011) 2.34
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood (2011) 2.33
Activation of thymic regeneration in mice and humans following androgen blockade. J Immunol (2005) 2.31
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood (2004) 2.28
Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells (2010) 2.25
Acute graft-versus-host disease: from the bench to the bedside. Blood (2009) 2.24
In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood (2008) 2.24
IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med (2007) 2.23
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J Exp Med (2013) 2.18
Leukocyte migration and graft-versus-host disease. Blood (2005) 2.17
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood (2007) 2.12
Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. Blood (2002) 2.03
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med (2013) 2.03
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood (2003) 1.97
Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood (2006) 1.92
Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood (2005) 1.89
The Snell dwarf mutation Pit1(dw) can increase life span in mice. Mech Ageing Dev (2002) 1.87
CD28 costimulation is essential for human T regulatory expansion and function. J Immunol (2008) 1.86
Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A (2004) 1.85
A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med (2012) 1.84
TALEN-based gene correction for epidermolysis bullosa. Mol Ther (2013) 1.84
Systemic delivery of Salmonella typhimurium transformed with IDO shRNA enhances intratumoral vector colonization and suppresses tumor growth. Cancer Res (2012) 1.84
mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia. Proc Natl Acad Sci U S A (2004) 1.83
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008) 1.82
In vivo imaging of graft-versus-host-disease in mice. Blood (2004) 1.78
Natural killer-cell differentiation by myeloid progenitors. Blood (2010) 1.75
Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood (2004) 1.73
miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood (2011) 1.73
Sustained thymopoiesis and improvement in functional immunity induced by exogenous KGF administration in murine models of aging. Blood (2006) 1.71
TCR affinity and specificity requirements for human regulatory T-cell function. Blood (2012) 1.69
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol (2012) 1.68
Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHC. Blood (2011) 1.68
Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol (2004) 1.68
Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9. Blood (2012) 1.67
IL-21 blockade reduces graft-versus-host disease mortality by supporting inducible T regulatory cell generation. Blood (2009) 1.67
Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. Blood (2010) 1.66
Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells. Blood (2008) 1.62
Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa. J Invest Dermatol (2010) 1.62
B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions [corrections]. J Immunol (2004) 1.60
Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol (2003) 1.59
Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood (2002) 1.58
Mechanisms of donor-specific transfusion tolerance: preemptive induction of clonal T-cell exhaustion via indirect presentation. Blood (2003) 1.57
CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood (2005) 1.53
Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol (2003) 1.53
Thymic T-cell development in allogeneic stem cell transplantation. Blood (2011) 1.53
Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity. Blood (2009) 1.51
Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood (2007) 1.51
PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection. J Immunol (2007) 1.51
Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood (2006) 1.51
Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. Nat Immunol (2011) 1.49